Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.
Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 6, 1, 4, 1 and 2 respectively.
Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypoglycemia - Overview
Hypoglycemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoglycemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoglycemia - Companies Involved in Therapeutics Development
Avolynt Inc
Boehringer Ingelheim International GmbH
Covis Pharmaceuticals Inc
CymaBay Therapeutics Inc
Eiger BioPharmaceuticals Inc
LATITUDE Pharmaceuticals Inc
NB Health Laboratory Co Ltd
Protomer Technologies Inc
Rezolute Inc
Twist Bioscience Corp
USV Pvt Ltd
Xeris Biopharma Holdings Inc
Zealand Pharma AS
Zosano Pharma Corp
Zucara Therapeutics Inc
Hypoglycemia - Drug Profiles
avexitide acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
AVO-3235 - Drug Profile
Product Description
Mechanism Of Action
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
History of Events
empagliflozin - Drug Profile
Product Description
Mechanism Of Action
History of Events
glucagon - Drug Profile
Product Description
Mechanism Of Action
History of Events
glucagon - Drug Profile
Product Description
Mechanism Of Action
History of Events
glucagon - Drug Profile
Product Description
Mechanism Of Action
glucagon - Drug Profile
Product Description
Mechanism Of Action
History of Events
glucagon - Drug Profile
Product Description
Mechanism Of Action
glucagon biosimilar - Drug Profile
Product Description
Mechanism Of Action
MBX-2982 - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-017 - Drug Profile
Product Description
Mechanism Of Action
Rescue-G - Drug Profile
Product Description
Mechanism Of Action
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TB-013 - Drug Profile
Product Description
Mechanism Of Action
ZT-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hypoglycemia - Dormant Projects
Hypoglycemia - Discontinued Products
Hypoglycemia - Product Development Milestones
Featured News & Press Releases
Feb 15, 2022: Zealand Pharma completes enrollment in phase 3 trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)
Dec 16, 2021: Xeris Biopharma announces the availability of Ogluo in the UK through its commercialization partner, Tetris Pharma
Sep 22, 2021: Rezolute presents results from two-week natural history study in congenital hyperinsulinism patients on standard of care therapies at ESPE 2021
Aug 23, 2021: Xeris Pharmaceuticals announces approval of supplemental new drug application (sNDA) of Gvoke Kit for the treatment of severe hypoglycemia
Aug 12, 2021: Zealand Pharma launches ZEGALOGUE (dasiglucagon) injection and advances pipeline programs across multiple therapeutic areas
Aug 05, 2021: Eiger announces FDA Breakthrough Therapy Designation for Avexitide for treatment of congenital hyperinsulinism
Jul 28, 2021: Zucara Therapeutics doses first patients in phase 1b trial of ZT-01
Jun 28, 2021: Eiger BioPharmaceuticals announces presentation of positive phase 2 results of avexitide in congenital hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session
Jun 24, 2021: Zealand Pharma announces U.S. commercial availability of ZEGALOGUE (dasiglucagon) injection
Jun 16, 2021: Zealand Pharma to present data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
May 26, 2021: Zucara Therapeutics successfully completes single and multiple ascending dose phase 1 trial of ZT-01
May 12, 2021: Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue (dasiglucagon) injection
May 03, 2021: Zealand Pharma announces publication of Phase 3 trial evaluating efficacy and safety of dasiglucagon for treatment of severe hypoglycemia in adult patients with diabetes
Apr 29, 2021: Xeris Pharmaceuticals receives U.K. MHRA approval of Ogluo (glucagon) Injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus
Mar 22, 2021: Rezolute presents data on RZ358 in post-gastric bypass hypoglycemia at ENDO 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hypoglycemia, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hypoglycemia - Pipeline by Avolynt Inc, 2022
Hypoglycemia - Pipeline by Boehringer Ingelheim International GmbH, 2022
Hypoglycemia - Pipeline by Covis Pharmaceuticals Inc, 2022
Hypoglycemia - Pipeline by CymaBay Therapeutics Inc, 2022
Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, 2022
Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, 2022
Hypoglycemia - Pipeline by NB Health Laboratory Co Ltd, 2022
Hypoglycemia - Pipeline by Protomer Technologies Inc, 2022
Hypoglycemia - Pipeline by Rezolute Inc, 2022
Hypoglycemia - Pipeline by Twist Bioscience Corp, 2022
Hypoglycemia - Pipeline by USV Pvt Ltd, 2022
Hypoglycemia - Pipeline by Xeris Biopharma Holdings Inc, 2022
Hypoglycemia - Pipeline by Zealand Pharma AS, 2022
Hypoglycemia - Pipeline by Zosano Pharma Corp, 2022
Hypoglycemia - Pipeline by Zucara Therapeutics Inc, 2022
Hypoglycemia - Dormant Projects, 2022
Hypoglycemia - Discontinued Products, 2022
List of Figures
Number of Products under Development for Hypoglycemia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
